Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Registrant’s telephone number, including area code: (760) 931-9200

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).

Emerging growth company                ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

On June 18, 2024, Ionis Pharmaceuticals, Inc. (“Ionis”) issued a press release announcing it has entered into an amended and restated license agreement with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) under which Otsuka obtains exclusive rights across the Asia-Pacific region to commercialize donidalorsen, an investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Ionis will maintain primary responsibility for the development of donidalorsen, while Otsuka will be responsible for territory-specific development, regulatory filings and commercialization in the Asia-Pacific region and Europe.

 

A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

 

(d) Exhibits.